Ying Cheng

45.0k total citations · 10 hit papers
424 papers, 10.0k citations indexed

About

Ying Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ying Cheng has authored 424 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 270 papers in Oncology, 241 papers in Pulmonary and Respiratory Medicine and 74 papers in Molecular Biology. Recurrent topics in Ying Cheng's work include Lung Cancer Treatments and Mutations (192 papers), Lung Cancer Research Studies (120 papers) and Colorectal Cancer Treatments and Studies (83 papers). Ying Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (192 papers), Lung Cancer Research Studies (120 papers) and Colorectal Cancer Treatments and Studies (83 papers). Ying Cheng collaborates with scholars based in China, United States and Japan. Ying Cheng's co-authors include Yi‐Long Wu, Tony Mok, Kazuhiko Nakagawa, Ki Hyeong Lee, Xiangdong Zhou, Rafael Rosell, Adam Płużański, Seiji Niho, Maria Rita Migliorino and Shukui Qin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ying Cheng

389 papers receiving 9.9k citations

Hit Papers

Dacomitinib versus gefitinib as first-line treatment for ... 2013 2026 2017 2021 2017 2015 2021 2013 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
    2017 854 citations Yi‐Long Wu, Ying Cheng et al. profile →
  2. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 553 citations Yihebali Chi, Ying Cheng et al. profile →
  3. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
    2021 484 citations Marina Chiara Garassino, Ying Cheng et al. Journal of Clinical Oncology profile →
  4. Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
    2013 417 citations Ying Cheng et al. Journal of Clinical Oncology profile →
  5. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
    2020 409 citations Luis Paz‐Ares, Ying Cheng et al. Journal of Thoracic Oncology profile →
  6. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
    2018 331 citations Ying Cheng, Yi‐Long Wu et al. Journal of Clinical Oncology profile →
  7. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    2019 265 citations Yi‐Long Wu, Ying Cheng et al. Journal of Thoracic Oncology profile →
  8. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
    2023 233 citations Silvia Novello, Ying Cheng et al. Journal of Clinical Oncology profile →
  9. Metal organic frameworks as efficient adsorbents for drugs from wastewater
    2022 194 citations Ying Cheng et al. profile →
  10. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ying Cheng China 47 7.0k 6.1k 2.1k 1.3k 938 424 10.0k
Noboru Yamamoto Japan 54 7.3k 1.0× 5.3k 0.9× 3.3k 1.6× 1.6k 1.2× 855 0.9× 513 11.8k
Tarek Mekhail United States 41 5.8k 0.8× 6.9k 1.1× 3.0k 1.4× 1.8k 1.4× 462 0.5× 170 10.6k
Toyoaki Hida Japan 61 8.1k 1.1× 8.5k 1.4× 4.0k 1.9× 2.0k 1.5× 753 0.8× 280 13.4k
Kōichi Goto Japan 50 6.6k 0.9× 6.4k 1.1× 3.4k 1.6× 1.9k 1.5× 1.2k 1.3× 497 10.8k
Rossana Berardi Italy 45 4.2k 0.6× 2.8k 0.5× 1.9k 0.9× 1.4k 1.0× 569 0.6× 344 7.4k
Rogério Lilenbaum United States 33 5.6k 0.8× 5.5k 0.9× 2.1k 1.0× 1.2k 0.9× 334 0.4× 105 8.4k
David M. Jackman United States 38 4.9k 0.7× 5.6k 0.9× 2.0k 1.0× 1.7k 1.3× 408 0.4× 87 7.6k
Fumihiro Tanaka Japan 48 3.8k 0.5× 4.4k 0.7× 2.3k 1.1× 1.5k 1.1× 561 0.6× 404 8.7k
Manuela Schmidinger Austria 33 3.0k 0.4× 5.4k 0.9× 3.9k 1.9× 2.3k 1.7× 658 0.7× 180 8.5k
Catherine Delbaldo France 20 6.3k 0.9× 2.7k 0.5× 1.8k 0.8× 2.2k 1.6× 1.5k 1.6× 48 8.3k

Countries citing papers authored by Ying Cheng

Since Specialization
Citations

This map shows the geographic impact of Ying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Cheng more than expected).

Fields of papers citing papers by Ying Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Cheng. The network helps show where Ying Cheng may publish in the future.

Co-authorship network of co-authors of Ying Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Cheng. A scholar is included among the top collaborators of Ying Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Cheng. Ying Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yunbo, et al.. (2025). Effect of different crystal phase of microsilica on bending strength for sodium silicate bonded sand cores. Ceramics International. 51(13). 18356–18361. 1 indexed citations
2.
Cheng, Ying, et al.. (2024). A Systematic Review and Meta-Analysis of the Detection of Shiga Toxin–Producing Escherichia coli in Cattle in China in the Past 10 Years. Foodborne Pathogens and Disease. 22(11). 737–747. 1 indexed citations
3.
Valdiviezo, Natalia, Pasi A. Jänne, Ying Cheng, et al.. (2024). MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC. Journal of Thoracic Oncology. 19(10). S102–S102. 5 indexed citations
4.
Li, Yunbo, et al.. (2024). Effect of Hydrophobic Fumed Silica on Bending Strength of Sodium Silicate-Bonded Sand Cores. Materials. 17(23). 5714–5714. 1 indexed citations
5.
Gadgeel, Shirish M., Delvys Rodríguez‐Abreu, Balázs Halmos, et al.. (2024). Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. Journal of Thoracic Oncology. 19(8). 1228–1241. 19 indexed citations
6.
Li, Qingling, Huarui Zhang, Ying Cheng, et al.. (2024). Effects of yttrium on microstructure and low cycle fatigue properties of superalloy IN713C at high temperature. International Journal of Fatigue. 189. 108541–108541. 2 indexed citations
7.
Ding, Xulong, Shuqiang Cao, Qing Wang, et al.. (2024). DNALI1 Promotes Neurodegeneration after Traumatic Brain Injury via Inhibition of Autophagosome‐Lysosome Fusion. Advanced Science. 11(15). e2306399–e2306399. 6 indexed citations
8.
9.
10.
Goto, Keiko, Benjamin Solomon, K. Park, et al.. (2023). LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Annals of Oncology. 34. S1303–S1303. 4 indexed citations
11.
Planchard, David, Pasi A. Jänne, Ying Cheng, et al.. (2023). 512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. Annals of Oncology. 34. S1668–S1668.
12.
Yao, Fangyi, Ying Cheng, Jing Liu, et al.. (2023). The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy. Genes & Diseases. 11(2). 993–1008. 7 indexed citations
13.
Chi, Yihebali, Xiangqian Zheng, Ying Cheng, et al.. (2023). Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial. Clinical Cancer Research. 29(20). 4047–4056. 15 indexed citations
14.
Chmielecki, Juliann, Jhanelle E. Gray, Ying Cheng, et al.. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14(1). 1070–1070. 130 indexed citations breakdown →
15.
16.
Li, Dapeng, Yihebali Chi, Minghua Ge, et al.. (2021). Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. Clinical Cancer Research. 27(13). 3567–3575. 78 indexed citations
17.
Peng, Zhi, Jia Wei, Wang Feng, et al.. (2021). Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 27(11). 3069–3078. 75 indexed citations
18.
Cheng, Ying, Yong He, Wěi Li, et al.. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted Oncology. 16(2). 165–176. 90 indexed citations
19.
Qu, Yue, et al.. (2019). Association of polymorphisms in MALAT1 with the risk of esophageal squamous cell carcinoma in a Chinese population. SHILAP Revista de lepidopterología. 3 indexed citations
20.
Hoff, Paulo M., Andreas Hochhaus, Bernhard C. Pestalozzi, et al.. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology. 30(29). 3596–3603. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noboru Yamamoto Breakdown of academic impact, for papers by Tarek Mekhail Breakdown of academic impact, for papers by Toyoaki Hida Breakdown of academic impact, for papers by Kōichi Goto Breakdown of academic impact, for papers by Rossana Berardi Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by David M. Jackman Breakdown of academic impact, for papers by Fumihiro Tanaka Breakdown of academic impact, for papers by Manuela Schmidinger Breakdown of academic impact, for papers by Catherine Delbaldo
Rankless by CCL
2026